Centers for Disease Control and Prevention (CDC). HIV/AIDS Among Women Fact Sheet. March2013. www.cdc.gov/hiv/pdf/risk_women.pdf. 2013 August 1.
2.
McDavidK, LiJ, LeeLM. Racial and ethnic disparities in HIV diagnoses for women in the United States. J Acquir Immune Defic Syndr, 2006; 42:101–107.
3.
HolmesKK, KaronJM, KreissJ. The increasing frequency of heterosexually acquired AIDS in the United States, 1983–88. Am J Public Health, 1990; 80:858–863.
4.
AdimoraAA, SchoenbachVJ, TaylorEM, KhanMR, SchwartzRJ. Concurrent partnerships, nonmonogamous partners, and substance use among women in the United States. Am J Public Health, 2011; 101:128–136.
5.
EdlinBR, IrwinKL, FaruqueSet al.Intersecting epidemics—crack cocaine use and HIV infection among inner-city young adults. Multicenter Crack Cocaine and HIV Infection Study Team. N Engl J Med, 1994; 331:1422–1427.
6.
BuchbinderSP, MehrotraDV, DuerrAet al.Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet, 2008; 372:1881–1893.
7.
SeageGR, HolteSE, MetzgerDet al.Are U.S. populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol, 2001; 153:619–627.
8.
FlynnNM, ForthalDN, HarroCDet al.Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis, 2005; 191:654–665.
9.
HallforsDD, IritaniBJ, MillerWC, BauerDJ. Sexual and drug behavior patterns and HIV and STD racial disparities: the need for new directions. Am J Public Health, 2007; 97:125–132.
PhelanJC, LinkBG. Controlling disease and creating disparities: A fundamental cause perspective. J Gerontol B Psychol Sci Soc Sci, 2005; 60,Spec No 2:27–33.
12.
RudolphAE, LintonS, DyerTP, LatkinC. Individual, network, and neighborhood correlates of exchange sex among female non-injection drug users in Baltimore, MD (2005–2007)AIDS Behav, 2013; 17:598–611.
13.
BoermaJT, WeirSS. Integrating demographic and epidemiological approaches to research on HIV/AIDS: The proximate-determinants framework. J Infect Dis, 2005; 191:S61–67.
14.
HodderSL, JustmanJ, HughesJPet al.HIV Acquisition among women from selected areas of the United States: A cohort study. Ann Intern Med, 2013; 158:10–18.
15.
KoblinBA, MetchB, NovakRMet al.Feasibility of identifying a cohort of US women at high risk for HIV infection for HIV vaccine efficacy trials: longitudinal results of HVTN 906. J Acquir Immune Defic Syndr, 2013; 63:239–244.
16.
Centers for Disease Control andPrevention (CDC). HIV infection among heterosexuals at increased risk —United States, 2010. MMWR Morb Mortal Wkly Rep, 2013; 62:183–188.
17.
PrejeanJ, SongR, HernandezAet al.Estimated HIV incidence in the United States, 2006–2009. PLoS One, 2011; 6:e17502.
18.
ReillyK, NeaigusA, JennessSM, HaganH, WendelT, Gelpi-AcostaC. High HIV prevalence among low-income, black women in New York City with self-reported HIV negative and unknown status. J Womens Health, 2013; 22:000–000.
19.
MuhibFB, LinLS, StueveAet al.A venue-based method for sampling hard-to-reach populations. Public Health Rep, 2001; 116:216–222.
20.
LanskyA, BrooksJT, DiNennoE, HeffelfingerJ, HallHI, MerminJ. Epidemiology of HIV in the United States. J Acquir Immune Defic Syndr, 2010; 55:S64–68.
21.
GoelS, SalganikMJ. Assessing respondent-driven sampling. Proc Natl Acad Sci U S A, 2010; 107:6743–6747.
22.
McCreeshN, FrostSD, SeeleyJet al.Evaluation of respondent-driven sampling. Epidemiology, 2012; 23:138–147.
23.
SalganikMJ. Commentary: Respondent-driven sampling in the real world. Epidemiology, 2012; 23:148–150.
24.
WylieJL, JollyAM. Understanding recruitment: Outcomes associated with alternate methods for seed selection in respondent driven sampling. BMC Med Res Methodol, 2013; 13:93.
25.
SalganikMJ. Variance estimation, design effects, and sample size calculations for respondent-driven sampling. J Urban Health, 2006; 83:i98–112.
